Drug Shortage Report for SANDOZ IRBESARTAN
Report ID | 247605 |
Drug Identification Number | 02328496 |
Brand name | SANDOZ IRBESARTAN |
Common or Proper name | IRBESARTAN |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | MARKETED |
Active Ingredient(s) | IRBESARTAN |
Strength(s) | 300MG |
Dosage form(s) | TABLET |
Route of administration | ORAL ORAL |
Packaging size | 500FCT |
ATC code | C09CA |
ATC description | ANGIOTENSIN II ANTAGONISTS, PLAIN |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2025-01-13 |
Estimated end date | 2025-01-31 |
Actual end date | 2025-02-03 |
Shortage status | Resolved |
Updated date | 2025-02-04 |
Company comments | |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v7 | 2025-02-04 | English | Compare |
v6 | 2025-02-03 | French | Compare |
v5 | 2025-02-03 | English | Compare |
v4 | 2025-01-20 | French | Compare |
v3 | 2025-01-20 | English | Compare |
v2 | 2025-01-13 | French | Compare |
v1 | 2025-01-13 | English | Compare |
Showing 1 to 7 of 7